DPT

DPT

DPT

Psychoactive Research chemicals are new synthetic substances that are structurally similar to the original drug, while being functional analogs. Research on the effects of, and treatment for, abuse of these drugs is limited due to the fact that they’re fairly new and have avoided mainstream notice. Research chemicals do not have a lot of human consumption data, and thus harm-reduction and special care should be taken if choosing to ingest them.

Psychedelics are drugs which cause profound changes in a one’s perceptions of reality, otherwise known as hallucinations. While under the influence of hallucinogens, users might see images, hear sounds or feel sensations. These chemicals offer some of the most intense psychological experiences and care should be taken when ingesting them.

Disclaimer: Psychedelic drugs offer some of the most power and intense psychological experiences. Additionally these substances are illegal in many places. We understand that even though these substances are illegal, their use occurs frequently. We do not condone breaking of the law. By providing accurate information about these substances, we encourage the user to make responsible decisions and practice harm reduction.

Read the full disclaimer here.

Practice Harm Reduction. Proceed with Caution.

Description

DPT

Also known as:

  • 1H-Indole-3-ethanamine, N,N-dipropyl-[ACD/Index Name]
  • DPT
  • N,N-Dipropyltryptamine(DPT)
  • N-[2-(1H-Indol-3-yl)ethyl]-N-propyl-1-propanamin[German][ACD/IUPAC Name]
  • N-[2-(1H-Indol-3-yl)ethyl]-N-propyl-1-propanamine[ACD/IUPAC Name]
  • N-[2-(1H-Indol-3-yl)éthyl]-N-propyl-1-propanamine[French][ACD/IUPAC Name]
  • N-[2-(1H-Indol-3-yl)ethyl]-N-propylpropan-1-amine
  • S7272VWU50
  • [2-(1H-INDOL-3-YL)ETHYL]DIPROPYLAMINE
  • [61-52-9]
  • 3-(2-(Dipropylamino)ethyl)indole
  • 3-(2-Dipropylaminoethyl) indole
  • '61-52-9
  • D-6500
  • Indole, 3-(2-(dipropylamino)ethyl)-
  • MFCD01718836[MDL number]
  • N-(2-(1H-Indol-3-yl)ethyl)-N-propylpropan-1-amine
  • N,N-Dipropyltryptamine free base
  • N,N-Dipropyltryptamine, free base
  • N-2-(1H-indol-3-yl)ethyl-N-propylpropan-1-amine[ACD/IUPAC Name]
  • NL8050000
  • UNII:S7272VWU50

N,N-Dipropyltryptamine, a psychedelic tryptamine compound and lesser-known analogue of DMT, with similar psychedelic effects. Like DMT it is a partial serotonin receptor agonist.

Summary

It is closely related to DMT and is reported to be uniquely similar in its hallucinogenic intensity, albeit with a moderately longer duration and greater unpredictability relative to DMT and other psychedelic tryptamines. DPT was first synthesized in 1950. Human use was first reported in 1973, where it was researched in low doses as an adjunct to therapy for alcoholism.

It has also been researched in high doses to induce peak experiences for terminal cancer patients. It has gained some notoriety for its adoption as the primary sacrament for the “Temple of the True Inner Light” in the United States, a Christian off-shoot organization who believe in the ritual use of psychedelics and refer to them as “the true flesh of God. " DPT is commonly consumed via insufflation or orally.

Many report the experience of insufflation to be very congestive and painful which, with the rapidness of onset, does not give the user much time to acclimate themselves to its powerful effects. It can also be administered intramuscularly or via vaporization after conversion to the freebase form. Smoking the freebase is reported to be the preferred route used by the “Temple of True Inner Light”.

Very little data exists about the pharmacological properties, metabolism, and toxicity of DPT, and it has relatively little history of human usage. It has long been available on the research chemicals market as a legal, grey-market alternative to DMT, and commercially distributed through online vendors. Many reports also suggest that this substance may be overly difficult to use safely for those who are not already very experienced with hallucinogens.

It is highly advised to approach this powerful psychedelic substance with the proper amount of precaution and harm reduction practices when using it.

History

Chemistry

DPT

DPT

Tryptamines share a core structure comprised of a bicyclic indole heterocycle attached at R3 to an amino group via an ethyl side chain.

DPT contains two propyl groups carbon chains bound to the terminal amine RN of its tryptamine backbone. DPT has a number of substituted analogs such as 4-HO-DPT or 4-AcO-DPT.

Common NameDipropyltryptamine
Systematic nameDipropyltryptamine
FormulaC_{16}H_{24}N_{2}
SMILESCCCN(CCC)CCc1c[nH]c2c1cccc2
Std. InChiInChI=1S/C16H24N2/c1-3-10-18(11-4-2)12-9-14-13-17-16-8-6-5-7-15(14)16/h5-8,13,17H,3-4,9-12H2,1-2H3
Std. InChiKeyBOOQTIHIKDDPRW-UHFFFAOYSA-N
Avg. Mass244.3752 Da
Molecular Weight244.3752
Monoisotopic Mass244.193954 Da
Nominal Mass244
ChemSpider ID5866

Subscribe for the latest updates

Dosing Guide

Oral
Light75-125mg
Common125-200mg
Strong200-250mg
Insufflated
Light20-50
Common50-100mg
Strong100-150mg
IM
Threshold5-10mg
Light10-35mg
Common35-60mg
Strong60-100mg

Duration

Oral
Onset20-60 minutes
Duration2-4 hours
After-effects2-3 hours

Interactions and Synergies

There are no existing interaction or synergy data for this drug.

General Information

Experiences
Oral
Vaporization
Come up
Dosage
EffectsA psychedelic tryptamine with "a wide range of effects at any particular dose depending on the individual"
After Effects
Avoid
Warning
Risks
Test Kits
Marguis Test Result
Tolerance
Detection
Half-life
Advice
Note
Note 2:
Note 3:

Effects

Pharmacological Effects

DPT’s psychedelic effects are believed to come from its efficacy at the 5-HT2A and 5-HT1A receptor as a partial agonist. The role of these interactions and how they result in the psychedelic experience remains the subject of ongoing scientific investigation.

Subjective Effects

Relative to psychedelic tryptamines like DMT, DPT is often reported to be similar in its hallucinogenic intensity, albeit with a moderately longer duration and more challenging effects. DPT experiences are often described as a “bizarre”, “unsettling”, and “darker” version of DMT experiences. DPT is reported to be more sensual and physical than DMT and other psychedelics with a corresponding amount of adverse physical effects.

Physical Effects

Psychological Effects

Visual Effects

Enhancements

Distortions

Geometry

DPT visual geometry can be described through its variations as intricate in complexity, both abstract and concrete in form, more digital than organic in feel, choppy and only loosely structured in organization, brightly lit, multicolored in scheme, sharp in its edges, fast in speed, simultaneously smooth and glitching in motion, immersive in depth, and consistent in intensity. At higher doses, it is more likely to result in states of level 8A geometry over level 8B.

Hallucinatory states

DPT produces a full range of high level hallucinatory states in a fashion that is more consistent and reproducible than that of any other commonly used psychedelic barring DMT and ibogaine. These effects include:

  • Transformations
  • Machinescapes - These are reported to be more common with DPT than with DMT, which lends to its common description as feeling more "industrial" and futuristic, while DMT visuals can often be described as "ancient" or "earthy" in feel.
  • Internal hallucination (autonomous entities; settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots) - As with DMT, DPT produces high level internal hallucinations at appropriate doses more consistently than most other psychedelics. They are more common within dark environments and can be comprehensively described through their variations as lucid in believability, interactive in style, new experiences in content, non-autonomous in controllability, geometry-based in style and almost exclusively of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental narrative in their overall theme, with a tendency towards chaotic disorganization and incoherence.
  • External hallucination (autonomous entities; settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots) - These are more common within dark environments and can be comprehensively described through their variations as lucid in believability, interactive in style, new experiences in content, non-autonomous in controllability, geometry-based in style and typically of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental narrative in their overall theme, with a tendency towards chaotic disorganization and incoherence.

Auditory Effects

Sensory Effects

  • Synaesthesia - In its fullest manifestation, this is a very rare and non-reproducible effect. Increasing the dosage can increase the likelihood of this occurring, but seems to only be a prominent part of the experience among those who are already predisposed to synaesthetic states.

Transpersonal Effects

Many reports indicate that while DPT possesses the raw hallucinogenic power to induce transpersonal states traditionally associated with "classical psychedelics", it does so in a significantly less consistent fashion due to the utter bizarreness and oft-noted "sinister", chaotic, or "forceful" undertones that can be present throughout the experience. What insights it can lead the user to typically occur during the aftermath and integration phase that follows, which shares some qualities of a typical near-death experience.

Legal Status

  • Germany: DPT is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
  • Latvia: DPT is a Schedule I controlled substance.
  • New Zealand: DPT is an analogue of DMT, so is a Class C controlled substance in New Zealand.
  • Sweden: Following its sale as a designer drug, DPT was made illegal in Sweden on January 26, 2016.
  • United Kingdom: DPT is a Class A controlled substance in the United Kingdom as a result of the tryptamine catch-all clause.
  • United States: DPT is unscheduled in the United States. It may be considered an analogue of DET, a Schedule I controlled substance under the Controlled Substances Act. As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act. DPT is a Schedule I controlled substance in the states of Florida, Maine, and Oklahoma making it illegal to buy, sell, or possess.

  • References

    1. Li, J. X.; Rice, K.; France, C. P. (2007). "Behavioral effects of dipropyltryptamine in rats: evidence for 5-HT1A and 5-HT2A agonist activity". Behavioural Pharmacology. 18 (4): 283–288. :10.1097/FBP.0b013e3281f19ca0.  1473-5849.  0955-8810. OCLC 22170289. PMID 17551320.
    2. Grof, S.; Soskin, R. A.; Richards, W. A.; Kurland, A. A. (1973). "DPT as an Adjunct in Psychotherapy of Alcoholics". International Pharmacopsychiatry. 8 (1): 104–115. :10.1159/000467979.  0020-8272. OCLC 1753673. PMID 4150711.
    3. Richards, W. A.; Rhead, J. C.; Dileo, F. B.; Yensen, R.; Kurland, A. A. (1977). "The Peak Experience Variable in DPT-Assisted Psychotherapy with Cancer Patients". Journal of Psychedelic Drugs. 9 (1): 1–10. :10.1080/02791072.1977.10472020.  0022-393X. OCLC 7565359.
    4. "Temple of the True Inner Light". Retrieved January 9, 2020.
    5. Fantegrossi, W. E.; Reissig, C. J.; Katz, E. B.; Yarosh, H. L.; Rice, K. C.; Winter, J. C. "Hallucinogen-like effects of N,N-dipropyltryptamine (DPT): Possible mediation by serotonin 5-HT1A and 5-HT2A receptors in rodents". Pharmacology Biochemistry and Behavior. 88 (3): 358–365. :10.1016/j.pbb.2007.09.007.  0091-3057. OCLC 848182005. PMC 2322878. PMID 17905422.
    6. Smith, D. A.; Bailey, J. M.; Williams, D.; Fantegrossi, W. E. (2014). "Tolerance and Cross-Tolerance to Head Twitch Behavior Elicited by Phenethylamine- and Tryptamine-Derived Hallucinogens in Mice". Journal of Pharmacology and Experimental Therapeutics. 351 (2): 485–491. :10.1124/jpet.114.219337.  1521-0103.  0022-3565. OCLC 1606914. PMC 4309922. PMID 25271256.
    7. Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. :10.1007/BF03161089.  1937-6995.  1556-9039. OCLC 163567183. PMC 3550327. PMID 19415589.
    8. "Anlage NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
    9. "Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes" (PDF). Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27 (in German). Bundesanzeiger Verlag. July 17, 2019. pp. 1083–1094. Retrieved January 1, 2020.
    10. "§ 4 NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
    11. "Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem" (in Latvian). VSIA Latvijas Vēstnesis. November 10, 2005. Retrieved January 1, 2020.
    12. "Schedule 1 Class A controlled drugs". "Reprint as at 13 August 2019: Misuse of Drugs Act 1975". Parliamentary Counsel Office. Retrieved January 7, 2020.
    13. "31 nya substanser klassas som narkotika eller hälsofarlig vara" (in Swedish). Folkhälsomyndigheten [Public Health Agency of Sweden]. January 26, 2016. Retrieved January 1, 2020.
    14. "Part I: Class A Drugs". "Misuse of Drugs Act 1971". UK Government. Retrieved January 7, 2020.
    15. "Title XLVI: Chapter 893: Drug Abuse Prevention And Control". The 2019 Florida Statutes. The Florida Legislature. Retrieved January 10, 2020.
    16. "Section 2-204 - Schedule I". Oklahoma Statutes Citationized. Oklahoma Judicial Center. January 11, 2019. Archived from the original on July 9, 2019. Retrieved January 10, 2020.

    Resources

    1. 1717 CheMall HE052356
    2. 1717 CheMall HE363332
    3. A&J Pharmtech AJ-32671
    4. AKos AKOS015967123
    5. Alichem A199007554
    6. ALK ALG00109839
    7. Amadis Chemical A833279
    8. American Custom Chemicals Corp API0016774
    9. Angene AGN-PC-04XNLY
    10. Ark Pharm, Inc. AK-77110
    11. Aurora Fine Chemicals K18.679.752
    12. BePharm B142340
    13. BGS International BG01541344
    14. BGS International BG04263314
    15. BGS International BG04573556
    16. Biosynth D-6500
    17. BOC Sciences 61-52-9
    18. Cayman Chemical CM147817
    19. CEG Chemical QC-9045
    20. ChEMBL CHEMBL1779153
    21. Chembo Pharma KB-258037
    22. Chemenu CM147817
    23. ChemIDplus 000061529
    24. ChemIDplus 61529
    25. Chemspace CSC016995038
    26. Collaborative Drug Discovery 42492
    27. DiscoveryGate 6091
    28. eMolecules 976843
    29. eNovation Chemicals D137386
    30. EPA DSSTox DTXCID80132338
    31. Erowid DPT
    32. FDA UNII - NLM S7272VWU50
    33. Finetech Industry FT-0629586
    34. iChemical EBD16201
    35. LabNetwork LN02166701
    36. LeadScope LS-83046
    37. Mcule MCULE-7107739457
    38. NIAID 517295
    39. NIST Spectra mainlib_334908
    40. OXchem AX8142340
    41. PubChem 6091
    42. PubMed 15516287
    43. PubMed 17223101
    44. PubMed 17905422
    45. Rosewachem RW094300
    46. Royal Society of Chemistry b008715g
    47. Royal Society of Chemistry b203057h
    48. Royal Society of Chemistry c1cp20420c
    49. RSC Learn Chemistry Wiki N,N-Dipropyltryptamine
    50. Springer Nature Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter
    51. Springer Nature Effects of phencyclidine and stress on plasma creatine phosphokinase (CPK) and aldolase activities in man
    52. Springer Nature Effects of psychotropic drugs on open-field behaviour in rats
    53. Springer Nature Serum CPK and aldolase activity in man following controlled administration of psychotomimetic drugs
    54. Springer Nature Simultaneous determination of tryptamine analogues in designer drugs using gas chromatographyu2013mass spectrometry and liquid chromatographyu2013tandem mass spectrometry
    55. Thomson Pharma 00513944
    56. Tractus Company Limited
    57. Wikidata Q2723010
    58. Wikipedia Dipropyltryptamine

    Sources

    Information made possible with:

    1. PsychonautWiki is a community-driven online encyclopedia that aims to document the field of psychonautics in a comprehensive, scientifically-grounded manner.
    2. Erowid is a non-profit educational & harm-reduction resource with 60 thousand pages of online information about psychoactive drugs
    3. PubChem National Center for Bio Informatics
    4. Chemspider is a free chemical structure database providing fast access to over 34 million structures, properties and associated information.
    5. Wikipedia

    Additional APIs were used to construct this information. Thanks for ChemSpider, NCBI, PubChem etc.

    Data is constantly updated so please check back later to see if there is any more available information on this substance.